DrugDev Selected for TransCelerate's Investigator Registry
TransCelerate BioPharma Inc. has selected DrugDev to develop and host its Investigator Registry
TransCelerate BioPharma Inc. has selected DrugDev to develop and host its Investigator Registry, which will allow TransCelerate member companies to pool investigator data together into a centralized, cloud-based resource utilizing a universal identifier known as the DrugDev Golden Number. The registry, along with TransCelerate’s Shared Investigator Platform, will help streamline some of the more inefficient clinical trial processes by offering the ability to expeditiously find investigator matches for their trials will drive improved performance.
For investigators, the registry expands their access to clinical trial opportunities by making them known throughout participating TransCelerate Member Companies. Moreover, making their investigator and site profile information available in the registry reduces the number of basic site information requests, which in turn allows them to spend more time focused on clinical activities.
DrugDev also is the third party host of the Investigator Databank.
Read the full release here.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
FDA-Approved Gene Therapy Beqvez Shows Sustained Efficacy, Safety in Long-Term Hemophilia B Trial
April 17th 2025Beqvez (fidanacogene elaparvovec), an FDA-approved one-time gene therapy for hemophilia B, demonstrated sustained factor IX expression, low bleeding rates, and a favorable safety profile over long-term follow-up.
